VRX Valeant Pharmaceuticals Interna

12.79
-0.14  -1%
Previous Close 12.93
Open 12.93
Price To book 1.16
Market Cap 4.45B
Shares 347,906,000
Volume 11,085,271
Short Ratio 1.73
Av. Daily Volume 24,919,500

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date August 24, 2017 (resubmission)
Latanoprostene bunod
Open angle glaucoma (OAG) or ocular hypertension (OHT)
Phase 3 enrollment to be completed in 2017.
Loteprednol Gel 0.38%
Ocular Inflammation
PDUFA date December 27, 2017.
Luminesse
Eye Brightener
Regulatory filing due 2H 2017.
IDP-122
Psoriasis
Regulatory filing due 2H 2017.
IDP-121
Acne
Phase 3 trial to be initiated 2H 2017.
IDP-120
Acne
Phase 3 data released January 10, 2017 - endpoints met. BLA filing due 1H 2017.
IDP-118
Psoriasis
Phase 3 trial to be initiated 2H 2017.
DP-123
Psoriasis
Phase 2 data due 1H 2017.
SAN-300
Rheumatoid Arthritis
Approved February 15, 2017.
Brodalumab
Psoriasis